Gemtuzumab is a humanized monoclonal antibody that belongs to the immunoglobulin G4 kappa (IgG4κ) subclass and is engineered as part of an antibody-drug conjugate (ADC) targeting the CD33 transmembrane receptor. Structurally, the antibody portion of Gemtuzumab is composed of two identical heavy chains and two identical light chains linked by disulfide bonds, forming the classical Y-shaped IgG configuration with a molecular weight of approximately 150 kilodaltons (kDa). It is expressed in mammalian cell systems such as Chinese Hamster Ovary (CHO) cells, which ensure proper folding, glycosylation, and structural stability. The variable regions (VH and VL) of the antibody are derived from murine sequences that confer specific recognition of CD33, while the constant regions are of human IgG4 origin to enhance tolerance and reduce Fc-mediated immune activation.
The antigen-binding fragments (Fab) of Gemtuzumab contain complementarity-determining regions (CDRs) that recognize an extracellular epitope on human CD33, a sialic acid-binding immunoglobulin-like lectin (Siglec) expressed on myeloid lineage cells. The high-affinity interaction involves hydrogen bonding and van der Waals forces, allowing selective binding to CD33-positive cells. As a therapeutic, Gemtuzumab is conjugated via a cleavable hydrazone linker to a cytotoxic payload, N-acetyl gamma calicheamicin dimethyl hydrazide, a DNA-damaging antitumor antibiotic. The linker is engineered to be stable in circulation but cleaved within acidic intracellular compartments following receptor-mediated endocytosis.
The Fc portion, derived from IgG4, minimizes antibody-dependent cellular cytotoxicity (ADCC) and complement activation, emphasizing intracellular delivery rather than immune effector activity.
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.
Have a product or application question? Consult our FAQs or contact us.
